#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0812] U.S.
1-1	0-1	[	_	_	
1-2	1-5	0812	_	_	
1-3	5-6	]	_	_	
1-4	7-10	U.S	_	_	
1-5	10-11	.	_	_	

#Text=Pat.
2-1	12-15	Pat	_	_	
2-2	15-16	.	_	_	

#Text=No. 6,495,518 also discloses that: "Similarly, delivery of nucleic acids has been problematic.
3-1	17-19	No	_	_	
3-2	19-20	.	_	_	
3-3	21-30	6,495,518	_	_	
3-4	31-35	also	_	_	
3-5	36-45	discloses	_	_	
3-6	46-50	that	_	_	
3-7	50-51	:	_	_	
3-8	52-53	"	_	_	
3-9	53-62	Similarly	_	_	
3-10	62-63	,	_	_	
3-11	64-72	delivery	*[1]	14-4[2_1]	
3-12	73-75	of	*[1]	_	
3-13	76-83	nucleic	*[1]	_	
3-14	84-89	acids	*[1]	_	
3-15	90-93	has	_	_	
3-16	94-98	been	_	_	
3-17	99-110	problematic	_	_	
3-18	110-111	.	_	_	

#Text=Methods currently employed include the permeabilization described above, with the above-described drawbacks, as well as vector-based delivery, such as with viral vectors, and liposome-mediated delivery.
4-1	112-119	Methods	_	_	
4-2	120-129	currently	_	_	
4-3	130-138	employed	_	_	
4-4	139-146	include	_	_	
4-5	147-150	the	_	_	
4-6	151-167	permeabilization	_	_	
4-7	168-177	described	_	_	
4-8	178-183	above	_	_	
4-9	183-184	,	_	_	
4-10	185-189	with	_	_	
4-11	190-193	the	_	_	
4-12	194-209	above-described	_	_	
4-13	210-219	drawbacks	_	_	
4-14	219-220	,	_	_	
4-15	221-223	as	_	_	
4-16	224-228	well	_	_	
4-17	229-231	as	_	_	
4-18	232-244	vector-based	_	_	
4-19	245-253	delivery	_	_	
4-20	253-254	,	_	_	
4-21	255-259	such	_	_	
4-22	260-262	as	_	_	
4-23	263-267	with	_	_	
4-24	268-273	viral	_	_	
4-25	274-281	vectors	_	_	
4-26	281-282	,	_	_	
4-27	283-286	and	_	_	
4-28	287-304	liposome-mediated	_	_	
4-29	305-313	delivery	_	_	
4-30	313-314	.	_	_	

#Text=However, viral vectors can present additional risks to a patient, and liposome techniques have not achieved satisfactorily high levels of delivery into cells."
#Text=[0813] U.S.
5-1	315-322	However	_	_	
5-2	322-323	,	_	_	
5-3	324-329	viral	_	_	
5-4	330-337	vectors	_	_	
5-5	338-341	can	_	_	
5-6	342-349	present	_	_	
5-7	350-360	additional	_	_	
5-8	361-366	risks	_	_	
5-9	367-369	to	_	_	
5-10	370-371	a	_	_	
5-11	372-379	patient	_	_	
5-12	379-380	,	_	_	
5-13	381-384	and	_	_	
5-14	385-393	liposome	_	_	
5-15	394-404	techniques	_	_	
5-16	405-409	have	_	_	
5-17	410-413	not	_	_	
5-18	414-422	achieved	_	_	
5-19	423-437	satisfactorily	_	_	
5-20	438-442	high	_	_	
5-21	443-449	levels	_	_	
5-22	450-452	of	_	_	
5-23	453-461	delivery	_	_	
5-24	462-466	into	_	_	
5-25	467-472	cells	_	_	
5-26	472-473	.	_	_	
5-27	473-474	"	_	_	
5-28	475-476	[	_	_	
5-29	476-480	0813	_	_	
5-30	480-481	]	_	_	
5-31	482-485	U.S	_	_	
5-32	485-486	.	_	_	

#Text=Pat.
6-1	487-490	Pat	_	_	
6-2	490-491	.	_	_	

#Text=No. 6,495,518 also discloses that "Signal peptide sequences . . . which share the common motif of hydrophobicity, mediate translocation of most intracellular secretory proteins across mammalian endoplasmic reticulum (ER) and prokaryotic plasma membranes through the putative protein-conducting channels.2-11 Alternative models for secretory protein transport also support a role for the signal sequence in targeting proteins to membranes . . . .
7-1	492-494	No	_	_	
7-2	494-495	.	_	_	
7-3	496-505	6,495,518	_	_	
7-4	506-510	also	_	_	
7-5	511-520	discloses	_	_	
7-6	521-525	that	_	_	
7-7	526-527	"	_	_	
7-8	527-533	Signal	_	_	
7-9	534-541	peptide	_	_	
7-10	542-551	sequences	_	_	
7-11	552-553	.	_	_	
7-12	554-555	.	_	_	
7-13	556-557	.	_	_	
7-14	558-563	which	_	_	
7-15	564-569	share	_	_	
7-16	570-573	the	_	_	
7-17	574-580	common	_	_	
7-18	581-586	motif	_	_	
7-19	587-589	of	_	_	
7-20	590-604	hydrophobicity	_	_	
7-21	604-605	,	_	_	
7-22	606-613	mediate	_	_	
7-23	614-627	translocation	_	_	
7-24	628-630	of	_	_	
7-25	631-635	most	_	_	
7-26	636-649	intracellular	_	_	
7-27	650-659	secretory	_	_	
7-28	660-668	proteins	_	_	
7-29	669-675	across	_	_	
7-30	676-685	mammalian	_	_	
7-31	686-697	endoplasmic	_	_	
7-32	698-707	reticulum	_	_	
7-33	708-709	(	_	_	
7-34	709-711	ER	_	_	
7-35	711-712	)	_	_	
7-36	713-716	and	_	_	
7-37	717-728	prokaryotic	_	_	
7-38	729-735	plasma	_	_	
7-39	736-745	membranes	_	_	
7-40	746-753	through	_	_	
7-41	754-757	the	_	_	
7-42	758-766	putative	_	_	
7-43	767-785	protein-conducting	_	_	
7-44	786-794	channels	_	_	
7-45	794-796	.2	_	_	
7-46	796-797	-	_	_	
7-47	797-799	11	_	_	
7-48	800-811	Alternative	_	_	
7-49	812-818	models	_	_	
7-50	819-822	for	_	_	
7-51	823-832	secretory	_	_	
7-52	833-840	protein	_	_	
7-53	841-850	transport	_	_	
7-54	851-855	also	_	_	
7-55	856-863	support	_	_	
7-56	864-865	a	_	_	
7-57	866-870	role	_	_	
7-58	871-874	for	_	_	
7-59	875-878	the	_	_	
7-60	879-885	signal	_	_	
7-61	886-894	sequence	_	_	
7-62	895-897	in	_	_	
7-63	898-907	targeting	_	_	
7-64	908-916	proteins	_	_	
7-65	917-919	to	_	_	
7-66	920-929	membranes	_	_	
7-67	930-931	.	_	_	
7-68	932-933	.	_	_	
7-69	934-935	.	_	_	
7-70	936-937	.	_	_	

#Text=Several types of signal sequence-mediated inside-out membrane translocation pathways have been proposed.
8-1	938-945	Several	_	_	
8-2	946-951	types	_	_	
8-3	952-954	of	_	_	
8-4	955-961	signal	_	_	
8-5	962-979	sequence-mediated	_	_	
8-6	980-990	inside-out	_	_	
8-7	991-999	membrane	_	_	
8-8	1000-1013	translocation	_	_	
8-9	1014-1022	pathways	_	_	
8-10	1023-1027	have	_	_	
8-11	1028-1032	been	_	_	
8-12	1033-1041	proposed	_	_	
8-13	1041-1042	.	_	_	

#Text=The major model implies that the proteins are transported across membranes through a hydrophilic protein conducting channel formed by a number of membrane proteins. 2-11 In eukaryotes, newly synthesized proteins in the cytoplasm are targeted to the ER membrane by signal sequences that are recognized generally by the signal recognition particle (SRP) and its ER membrane receptors.
9-1	1043-1046	The	_	_	
9-2	1047-1052	major	_	_	
9-3	1053-1058	model	_	_	
9-4	1059-1066	implies	_	_	
9-5	1067-1071	that	_	_	
9-6	1072-1075	the	_	_	
9-7	1076-1084	proteins	_	_	
9-8	1085-1088	are	_	_	
9-9	1089-1100	transported	_	_	
9-10	1101-1107	across	_	_	
9-11	1108-1117	membranes	_	_	
9-12	1118-1125	through	_	_	
9-13	1126-1127	a	_	_	
9-14	1128-1139	hydrophilic	_	_	
9-15	1140-1147	protein	_	_	
9-16	1148-1158	conducting	_	_	
9-17	1159-1166	channel	_	_	
9-18	1167-1173	formed	_	_	
9-19	1174-1176	by	_	_	
9-20	1177-1178	a	_	_	
9-21	1179-1185	number	_	_	
9-22	1186-1188	of	_	_	
9-23	1189-1197	membrane	_	_	
9-24	1198-1206	proteins	_	_	
9-25	1206-1207	.	_	_	
9-26	1208-1209	2	_	_	
9-27	1209-1210	-	_	_	
9-28	1210-1212	11	_	_	
9-29	1213-1215	In	_	_	
9-30	1216-1226	eukaryotes	_	_	
9-31	1226-1227	,	_	_	
9-32	1228-1233	newly	_	_	
9-33	1234-1245	synthesized	_	_	
9-34	1246-1254	proteins	_	_	
9-35	1255-1257	in	_	_	
9-36	1258-1261	the	_	_	
9-37	1262-1271	cytoplasm	_	_	
9-38	1272-1275	are	_	_	
9-39	1276-1284	targeted	_	_	
9-40	1285-1287	to	_	_	
9-41	1288-1291	the	_	_	
9-42	1292-1294	ER	_	_	
9-43	1295-1303	membrane	_	_	
9-44	1304-1306	by	_	_	
9-45	1307-1313	signal	_	_	
9-46	1314-1323	sequences	_	_	
9-47	1324-1328	that	_	_	
9-48	1329-1332	are	_	_	
9-49	1333-1343	recognized	_	_	
9-50	1344-1353	generally	_	_	
9-51	1354-1356	by	_	_	
9-52	1357-1360	the	_	_	
9-53	1361-1367	signal	_	_	
9-54	1368-1379	recognition	_	_	
9-55	1380-1388	particle	_	_	
9-56	1389-1390	(	_	_	
9-57	1390-1393	SRP	_	_	
9-58	1393-1394	)	_	_	
9-59	1395-1398	and	_	_	
9-60	1399-1402	its	_	_	
9-61	1403-1405	ER	_	_	
9-62	1406-1414	membrane	_	_	
9-63	1415-1424	receptors	_	_	
9-64	1424-1425	.	_	_	

#Text=This targeting step is followed by the actual transfer of protein across the ER membrane and out of the cell through the putative protein-conducting channel (for recent reviews, see references 2-5).
10-1	1426-1430	This	_	_	
10-2	1431-1440	targeting	_	_	
10-3	1441-1445	step	_	_	
10-4	1446-1448	is	_	_	
10-5	1449-1457	followed	_	_	
10-6	1458-1460	by	_	_	
10-7	1461-1464	the	_	_	
10-8	1465-1471	actual	_	_	
10-9	1472-1480	transfer	_	_	
10-10	1481-1483	of	_	_	
10-11	1484-1491	protein	_	_	
10-12	1492-1498	across	_	_	
10-13	1499-1502	the	_	_	
10-14	1503-1505	ER	_	_	
10-15	1506-1514	membrane	_	_	
10-16	1515-1518	and	_	_	
10-17	1519-1522	out	_	_	
10-18	1523-1525	of	_	_	
10-19	1526-1529	the	_	_	
10-20	1530-1534	cell	_	_	
10-21	1535-1542	through	_	_	
10-22	1543-1546	the	_	_	
10-23	1547-1555	putative	_	_	
10-24	1556-1574	protein-conducting	_	_	
10-25	1575-1582	channel	_	_	
10-26	1583-1584	(	_	_	
10-27	1584-1587	for	_	_	
10-28	1588-1594	recent	_	_	
10-29	1595-1602	reviews	_	_	
10-30	1602-1603	,	_	_	
10-31	1604-1607	see	_	_	
10-32	1608-1618	references	_	_	
10-33	1619-1620	2	_	_	
10-34	1620-1621	-	_	_	
10-35	1621-1622	5	_	_	
10-36	1622-1623	)	_	_	
10-37	1623-1624	.	_	_	

#Text=In bacteria, the transport of most proteins across the cytoplasmic membrane also requires a similar protein-conducting channel. 7-11On the other hand, signal peptides can interact strongly with lipids, supporting the proposal that the transport of some secretory proteins across cellular membranes may occur directly through the lipid bilayer in the absence of any proteinaceous channels . . . . "
#Text=[0814] U.S.
11-1	1625-1627	In	_	_	
11-2	1628-1636	bacteria	_	_	
11-3	1636-1637	,	_	_	
11-4	1638-1641	the	_	_	
11-5	1642-1651	transport	_	_	
11-6	1652-1654	of	_	_	
11-7	1655-1659	most	_	_	
11-8	1660-1668	proteins	_	_	
11-9	1669-1675	across	_	_	
11-10	1676-1679	the	_	_	
11-11	1680-1691	cytoplasmic	_	_	
11-12	1692-1700	membrane	_	_	
11-13	1701-1705	also	_	_	
11-14	1706-1714	requires	_	_	
11-15	1715-1716	a	_	_	
11-16	1717-1724	similar	_	_	
11-17	1725-1743	protein-conducting	_	_	
11-18	1744-1751	channel	_	_	
11-19	1751-1752	.	_	_	
11-20	1753-1754	7	_	_	
11-21	1754-1755	-	_	_	
11-22	1755-1759	11On	_	_	
11-23	1760-1763	the	_	_	
11-24	1764-1769	other	_	_	
11-25	1770-1774	hand	_	_	
11-26	1774-1775	,	_	_	
11-27	1776-1782	signal	_	_	
11-28	1783-1791	peptides	_	_	
11-29	1792-1795	can	_	_	
11-30	1796-1804	interact	_	_	
11-31	1805-1813	strongly	_	_	
11-32	1814-1818	with	_	_	
11-33	1819-1825	lipids	_	_	
11-34	1825-1826	,	_	_	
11-35	1827-1837	supporting	_	_	
11-36	1838-1841	the	_	_	
11-37	1842-1850	proposal	_	_	
11-38	1851-1855	that	_	_	
11-39	1856-1859	the	_	_	
11-40	1860-1869	transport	_	_	
11-41	1870-1872	of	_	_	
11-42	1873-1877	some	_	_	
11-43	1878-1887	secretory	_	_	
11-44	1888-1896	proteins	_	_	
11-45	1897-1903	across	_	_	
11-46	1904-1912	cellular	_	_	
11-47	1913-1922	membranes	_	_	
11-48	1923-1926	may	_	_	
11-49	1927-1932	occur	_	_	
11-50	1933-1941	directly	_	_	
11-51	1942-1949	through	_	_	
11-52	1950-1953	the	_	_	
11-53	1954-1959	lipid	_	_	
11-54	1960-1967	bilayer	_	_	
11-55	1968-1970	in	_	_	
11-56	1971-1974	the	_	_	
11-57	1975-1982	absence	_	_	
11-58	1983-1985	of	_	_	
11-59	1986-1989	any	_	_	
11-60	1990-2003	proteinaceous	_	_	
11-61	2004-2012	channels	_	_	
11-62	2013-2014	.	_	_	
11-63	2015-2016	.	_	_	
11-64	2017-2018	.	_	_	
11-65	2019-2020	.	_	_	
11-66	2021-2022	"	_	_	
11-67	2023-2024	[	_	_	
11-68	2024-2028	0814	_	_	
11-69	2028-2029	]	_	_	
11-70	2030-2033	U.S	_	_	
11-71	2033-2034	.	_	_	

#Text=Pat.
12-1	2035-2038	Pat	_	_	
12-2	2038-2039	.	_	_	

#Text=No. 6,495,518 also discloses that "Thus, though many attempts have been made to develop effective methods for importing biologically active molecules into cells, both in vivo and in vitro, none has proved to be entirely satisfactory."
13-1	2040-2042	No	_	_	
13-2	2042-2043	.	_	_	
13-3	2044-2053	6,495,518	_	_	
13-4	2054-2058	also	_	_	
13-5	2059-2068	discloses	_	_	
13-6	2069-2073	that	_	_	
13-7	2074-2075	"	_	_	
13-8	2075-2079	Thus	_	_	
13-9	2079-2080	,	_	_	
13-10	2081-2087	though	_	_	
13-11	2088-2092	many	_	_	
13-12	2093-2101	attempts	_	_	
13-13	2102-2106	have	_	_	
13-14	2107-2111	been	_	_	
13-15	2112-2116	made	_	_	
13-16	2117-2119	to	_	_	
13-17	2120-2127	develop	_	_	
13-18	2128-2137	effective	_	_	
13-19	2138-2145	methods	_	_	
13-20	2146-2149	for	_	_	
13-21	2150-2159	importing	_	_	
13-22	2160-2172	biologically	_	_	
13-23	2173-2179	active	_	_	
13-24	2180-2189	molecules	_	_	
13-25	2190-2194	into	_	_	
13-26	2195-2200	cells	_	_	
13-27	2200-2201	,	_	_	
13-28	2202-2206	both	_	_	
13-29	2207-2209	in	_	_	
13-30	2210-2214	vivo	_	_	
13-31	2215-2218	and	_	_	
13-32	2219-2221	in	_	_	
13-33	2222-2227	vitro	_	_	
13-34	2227-2228	,	_	_	
13-35	2229-2233	none	_	_	
13-36	2234-2237	has	_	_	
13-37	2238-2244	proved	_	_	
13-38	2245-2247	to	_	_	
13-39	2248-2250	be	_	_	
13-40	2251-2259	entirely	_	_	
13-41	2260-2272	satisfactory	_	_	
13-42	2272-2273	.	_	_	
13-43	2273-2274	"	_	_	

#Text=The solution to this problem, presented in claim 1 of the patent, is: "A method of importing a nuclear localization sequence of NF-.kappa.B into a cell in a subject, comprising administering a cyclic peptide consisting essentially of . . . to the subject, wherein said cyclic peptide is imported into a cell in the subject."
#Text=[0815] The process described in U.S.
14-1	2275-2278	The	_	_	
14-2	2279-2287	solution	_	_	
14-3	2288-2290	to	_	_	
14-4	2291-2295	this	*[2]	_	
14-5	2296-2303	problem	*[2]	_	
14-6	2303-2304	,	_	_	
14-7	2305-2314	presented	_	_	
14-8	2315-2317	in	_	_	
14-9	2318-2323	claim	_	_	
14-10	2324-2325	1	_	_	
14-11	2326-2328	of	_	_	
14-12	2329-2332	the	_	_	
14-13	2333-2339	patent	_	_	
14-14	2339-2340	,	_	_	
14-15	2341-2343	is	_	_	
14-16	2343-2344	:	_	_	
14-17	2345-2346	"	_	_	
14-18	2346-2347	A	_	_	
14-19	2348-2354	method	_	_	
14-20	2355-2357	of	_	_	
14-21	2358-2367	importing	_	_	
14-22	2368-2369	a	_	_	
14-23	2370-2377	nuclear	_	_	
14-24	2378-2390	localization	_	_	
14-25	2391-2399	sequence	_	_	
14-26	2400-2402	of	_	_	
14-27	2403-2405	NF	_	_	
14-28	2405-2406	-	_	_	
14-29	2406-2407	.	_	_	
14-30	2407-2414	kappa.B	_	_	
14-31	2415-2419	into	_	_	
14-32	2420-2421	a	_	_	
14-33	2422-2426	cell	_	_	
14-34	2427-2429	in	_	_	
14-35	2430-2431	a	_	_	
14-36	2432-2439	subject	_	_	
14-37	2439-2440	,	_	_	
14-38	2441-2451	comprising	_	_	
14-39	2452-2465	administering	_	_	
14-40	2466-2467	a	_	_	
14-41	2468-2474	cyclic	_	_	
14-42	2475-2482	peptide	_	_	
14-43	2483-2493	consisting	_	_	
14-44	2494-2505	essentially	_	_	
14-45	2506-2508	of	_	_	
14-46	2509-2510	.	_	_	
14-47	2511-2512	.	_	_	
14-48	2513-2514	.	_	_	
14-49	2515-2517	to	_	_	
14-50	2518-2521	the	_	_	
14-51	2522-2529	subject	_	_	
14-52	2529-2530	,	_	_	
14-53	2531-2538	wherein	_	_	
14-54	2539-2543	said	_	_	
14-55	2544-2550	cyclic	_	_	
14-56	2551-2558	peptide	_	_	
14-57	2559-2561	is	_	_	
14-58	2562-2570	imported	_	_	
14-59	2571-2575	into	_	_	
14-60	2576-2577	a	_	_	
14-61	2578-2582	cell	_	_	
14-62	2583-2585	in	_	_	
14-63	2586-2589	the	_	_	
14-64	2590-2597	subject	_	_	
14-65	2597-2598	.	_	_	
14-66	2598-2599	"	_	_	
14-67	2600-2601	[	_	_	
14-68	2601-2605	0815	_	_	
14-69	2605-2606	]	_	_	
14-70	2607-2610	The	_	_	
14-71	2611-2618	process	_	_	
14-72	2619-2628	described	_	_	
14-73	2629-2631	in	_	_	
14-74	2632-2635	U.S	_	_	
14-75	2635-2636	.	_	_	

#Text=Pat.
15-1	2637-2640	Pat	_	_	
15-2	2640-2641	.	_	_	

#Text=No. 6,495,518 may be used in conjunction with one or more of the therapeutic agents described elsewhere in this disclosure.
16-1	2642-2644	No	_	_	
16-2	2644-2645	.	_	_	
16-3	2646-2655	6,495,518	_	_	
16-4	2656-2659	may	_	_	
16-5	2660-2662	be	_	_	
16-6	2663-2667	used	_	_	
16-7	2668-2670	in	_	_	
16-8	2671-2682	conjunction	_	_	
16-9	2683-2687	with	_	_	
16-10	2688-2691	one	_	_	
16-11	2692-2694	or	_	_	
16-12	2695-2699	more	_	_	
16-13	2700-2702	of	_	_	
16-14	2703-2706	the	_	_	
16-15	2707-2718	therapeutic	_	_	
16-16	2719-2725	agents	_	_	
16-17	2726-2735	described	_	_	
16-18	2736-2745	elsewhere	_	_	
16-19	2746-2748	in	_	_	
16-20	2749-2753	this	_	_	
16-21	2754-2764	disclosure	_	_	
16-22	2764-2765	.	_	_	

#Text=In particular, such process may be used in conjunction with the nuclear localization sequence (NLS) which directs a moiety, to which it is attached, to the nucleus of the cell.
17-1	2766-2768	In	_	_	
17-2	2769-2779	particular	_	_	
17-3	2779-2780	,	_	_	
17-4	2781-2785	such	_	_	
17-5	2786-2793	process	_	_	
17-6	2794-2797	may	_	_	
17-7	2798-2800	be	_	_	
17-8	2801-2805	used	_	_	
17-9	2806-2808	in	_	_	
17-10	2809-2820	conjunction	_	_	
17-11	2821-2825	with	_	_	
17-12	2826-2829	the	_	_	
17-13	2830-2837	nuclear	_	_	
17-14	2838-2850	localization	_	_	
17-15	2851-2859	sequence	_	_	
17-16	2860-2861	(	_	_	
17-17	2861-2864	NLS	_	_	
17-18	2864-2865	)	_	_	
17-19	2866-2871	which	_	_	
17-20	2872-2879	directs	_	_	
17-21	2880-2881	a	_	_	
17-22	2882-2888	moiety	_	_	
17-23	2888-2889	,	_	_	
17-24	2890-2892	to	_	_	
17-25	2893-2898	which	_	_	
17-26	2899-2901	it	_	_	
17-27	2902-2904	is	_	_	
17-28	2905-2913	attached	_	_	
17-29	2913-2914	,	_	_	
17-30	2915-2917	to	_	_	
17-31	2918-2921	the	_	_	
17-32	2922-2929	nucleus	_	_	
17-33	2930-2932	of	_	_	
17-34	2933-2936	the	_	_	
17-35	2937-2941	cell	_	_	
17-36	2941-2942	.	_	_	

#Text=The NLS is a short peptide usually, (but not limited to) 4 to 8 amino acid residues usually, but not limited to, highly charged species such as lysine or arginine, which can be covalently bound to the therapeutic molecule or other chemical of interest.
#Text=[0816] Nuclear localization sequences are well known to those skilled in the art.
18-1	2943-2946	The	_	_	
18-2	2947-2950	NLS	_	_	
18-3	2951-2953	is	_	_	
18-4	2954-2955	a	_	_	
18-5	2956-2961	short	_	_	
18-6	2962-2969	peptide	_	_	
18-7	2970-2977	usually	_	_	
18-8	2977-2978	,	_	_	
18-9	2979-2980	(	_	_	
18-10	2980-2983	but	_	_	
18-11	2984-2987	not	_	_	
18-12	2988-2995	limited	_	_	
18-13	2996-2998	to	_	_	
18-14	2998-2999	)	_	_	
18-15	3000-3001	4	_	_	
18-16	3002-3004	to	_	_	
18-17	3005-3006	8	_	_	
18-18	3007-3012	amino	_	_	
18-19	3013-3017	acid	_	_	
18-20	3018-3026	residues	_	_	
18-21	3027-3034	usually	_	_	
18-22	3034-3035	,	_	_	
18-23	3036-3039	but	_	_	
18-24	3040-3043	not	_	_	
18-25	3044-3051	limited	_	_	
18-26	3052-3054	to	_	_	
18-27	3054-3055	,	_	_	
18-28	3056-3062	highly	_	_	
18-29	3063-3070	charged	_	_	
18-30	3071-3078	species	_	_	
18-31	3079-3083	such	_	_	
18-32	3084-3086	as	_	_	
18-33	3087-3093	lysine	_	_	
18-34	3094-3096	or	_	_	
18-35	3097-3105	arginine	_	_	
18-36	3105-3106	,	_	_	
18-37	3107-3112	which	_	_	
18-38	3113-3116	can	_	_	
18-39	3117-3119	be	_	_	
18-40	3120-3130	covalently	_	_	
18-41	3131-3136	bound	_	_	
18-42	3137-3139	to	_	_	
18-43	3140-3143	the	_	_	
18-44	3144-3155	therapeutic	_	_	
18-45	3156-3164	molecule	_	_	
18-46	3165-3167	or	_	_	
18-47	3168-3173	other	_	_	
18-48	3174-3182	chemical	_	_	
18-49	3183-3185	of	_	_	
18-50	3186-3194	interest	_	_	
18-51	3194-3195	.	_	_	
18-52	3196-3197	[	_	_	
18-53	3197-3201	0816	_	_	
18-54	3201-3202	]	_	_	
18-55	3203-3210	Nuclear	_	_	
18-56	3211-3223	localization	_	_	
18-57	3224-3233	sequences	_	_	
18-58	3234-3237	are	_	_	
18-59	3238-3242	well	_	_	
18-60	3243-3248	known	_	_	
18-61	3249-3251	to	_	_	
18-62	3252-3257	those	_	_	
18-63	3258-3265	skilled	_	_	
18-64	3266-3268	in	_	_	
18-65	3269-3272	the	_	_	
18-66	3273-3276	art	_	_	
18-67	3276-3277	.	_	_	

#Text=Thus, by way of illustration, reference may be had to U.S.
19-1	3278-3282	Thus	_	_	
19-2	3282-3283	,	_	_	
19-3	3284-3286	by	_	_	
19-4	3287-3290	way	_	_	
19-5	3291-3293	of	_	_	
19-6	3294-3306	illustration	_	_	
19-7	3306-3307	,	_	_	
19-8	3308-3317	reference	_	_	
19-9	3318-3321	may	_	_	
19-10	3322-3324	be	_	_	
19-11	3325-3328	had	_	_	
19-12	3329-3331	to	_	_	
19-13	3332-3335	U.S	_	_	
19-14	3335-3336	.	_	_	

#Text=Pat.
20-1	3337-3340	Pat	_	_	
20-2	3340-3341	.	_	_	

#Text=No. 6,521,456, the entire disclosure of which is hereby incorporated by reference into this specification.
21-1	3342-3344	No	_	_	
21-2	3344-3345	.	_	_	
21-3	3346-3355	6,521,456	_	_	
21-4	3355-3356	,	_	_	
21-5	3357-3360	the	_	_	
21-6	3361-3367	entire	_	_	
21-7	3368-3378	disclosure	_	_	
21-8	3379-3381	of	_	_	
21-9	3382-3387	which	_	_	
21-10	3388-3390	is	_	_	
21-11	3391-3397	hereby	_	_	
21-12	3398-3410	incorporated	_	_	
21-13	3411-3413	by	_	_	
21-14	3414-3423	reference	_	_	
21-15	3424-3428	into	_	_	
21-16	3429-3433	this	_	_	
21-17	3434-3447	specification	_	_	
21-18	3447-3448	.	_	_	

#Text=This patent is enitled "Cellular transport system for the transfer of a nucleic acid through the nuclear envelope and methods thereof," it discloses a method to use NLSs to transport transgenic nucleic acid molecules to the nucleus, and it claims "a nuclear transport agent for transferring a nucleic acid from cytoplasm into a nucleus of a eukaryotic cell comprising a first module and a second module, wherein the first module is module A that binds specifically to a DNA molecule so as not to form complexes consisting of more than one DNA molecule, and wherein the second module is module B that comprises an extended nuclear localization signal having a charge thus preventing the second module from mediating nonspecific binding of the nuclear transport agent to the DNA molecule."
22-1	3449-3453	This	_	_	
22-2	3454-3460	patent	_	_	
22-3	3461-3463	is	_	_	
22-4	3464-3471	enitled	_	_	
22-5	3472-3473	"	_	_	
22-6	3473-3481	Cellular	_	_	
22-7	3482-3491	transport	_	_	
22-8	3492-3498	system	_	_	
22-9	3499-3502	for	_	_	
22-10	3503-3506	the	_	_	
22-11	3507-3515	transfer	_	_	
22-12	3516-3518	of	_	_	
22-13	3519-3520	a	_	_	
22-14	3521-3528	nucleic	_	_	
22-15	3529-3533	acid	_	_	
22-16	3534-3541	through	_	_	
22-17	3542-3545	the	_	_	
22-18	3546-3553	nuclear	_	_	
22-19	3554-3562	envelope	_	_	
22-20	3563-3566	and	_	_	
22-21	3567-3574	methods	_	_	
22-22	3575-3582	thereof	_	_	
22-23	3582-3583	,	_	_	
22-24	3583-3584	"	_	_	
22-25	3585-3587	it	_	_	
22-26	3588-3597	discloses	_	_	
22-27	3598-3599	a	_	_	
22-28	3600-3606	method	_	_	
22-29	3607-3609	to	_	_	
22-30	3610-3613	use	_	_	
22-31	3614-3618	NLSs	_	_	
22-32	3619-3621	to	_	_	
22-33	3622-3631	transport	_	_	
22-34	3632-3642	transgenic	_	_	
22-35	3643-3650	nucleic	_	_	
22-36	3651-3655	acid	_	_	
22-37	3656-3665	molecules	_	_	
22-38	3666-3668	to	_	_	
22-39	3669-3672	the	_	_	
22-40	3673-3680	nucleus	_	_	
22-41	3680-3681	,	_	_	
22-42	3682-3685	and	_	_	
22-43	3686-3688	it	_	_	
22-44	3689-3695	claims	_	_	
22-45	3696-3697	"	_	_	
22-46	3697-3698	a	_	_	
22-47	3699-3706	nuclear	_	_	
22-48	3707-3716	transport	_	_	
22-49	3717-3722	agent	_	_	
22-50	3723-3726	for	_	_	
22-51	3727-3739	transferring	_	_	
22-52	3740-3741	a	_	_	
22-53	3742-3749	nucleic	_	_	
22-54	3750-3754	acid	_	_	
22-55	3755-3759	from	_	_	
22-56	3760-3769	cytoplasm	_	_	
22-57	3770-3774	into	_	_	
22-58	3775-3776	a	_	_	
22-59	3777-3784	nucleus	_	_	
22-60	3785-3787	of	_	_	
22-61	3788-3789	a	_	_	
22-62	3790-3800	eukaryotic	_	_	
22-63	3801-3805	cell	_	_	
22-64	3806-3816	comprising	_	_	
22-65	3817-3818	a	_	_	
22-66	3819-3824	first	_	_	
22-67	3825-3831	module	_	_	
22-68	3832-3835	and	_	_	
22-69	3836-3837	a	_	_	
22-70	3838-3844	second	_	_	
22-71	3845-3851	module	_	_	
22-72	3851-3852	,	_	_	
22-73	3853-3860	wherein	_	_	
22-74	3861-3864	the	_	_	
22-75	3865-3870	first	_	_	
22-76	3871-3877	module	_	_	
22-77	3878-3880	is	_	_	
22-78	3881-3887	module	_	_	
22-79	3888-3889	A	_	_	
22-80	3890-3894	that	_	_	
22-81	3895-3900	binds	_	_	
22-82	3901-3913	specifically	_	_	
22-83	3914-3916	to	_	_	
22-84	3917-3918	a	_	_	
22-85	3919-3922	DNA	_	_	
22-86	3923-3931	molecule	_	_	
22-87	3932-3934	so	_	_	
22-88	3935-3937	as	_	_	
22-89	3938-3941	not	_	_	
22-90	3942-3944	to	_	_	
22-91	3945-3949	form	_	_	
22-92	3950-3959	complexes	_	_	
22-93	3960-3970	consisting	_	_	
22-94	3971-3973	of	_	_	
22-95	3974-3978	more	_	_	
22-96	3979-3983	than	_	_	
22-97	3984-3987	one	_	_	
22-98	3988-3991	DNA	_	_	
22-99	3992-4000	molecule	_	_	
22-100	4000-4001	,	_	_	
22-101	4002-4005	and	_	_	
22-102	4006-4013	wherein	_	_	
22-103	4014-4017	the	_	_	
22-104	4018-4024	second	_	_	
22-105	4025-4031	module	_	_	
22-106	4032-4034	is	_	_	
22-107	4035-4041	module	_	_	
22-108	4042-4043	B	_	_	
22-109	4044-4048	that	_	_	
22-110	4049-4058	comprises	_	_	
22-111	4059-4061	an	_	_	
22-112	4062-4070	extended	_	_	
22-113	4071-4078	nuclear	_	_	
22-114	4079-4091	localization	_	_	
22-115	4092-4098	signal	_	_	
22-116	4099-4105	having	_	_	
22-117	4106-4107	a	_	_	
22-118	4108-4114	charge	_	_	
22-119	4115-4119	thus	_	_	
22-120	4120-4130	preventing	_	_	
22-121	4131-4134	the	_	_	
22-122	4135-4141	second	_	_	
22-123	4142-4148	module	_	_	
22-124	4149-4153	from	_	_	
22-125	4154-4163	mediating	_	_	
22-126	4164-4175	nonspecific	_	_	
22-127	4176-4183	binding	_	_	
22-128	4184-4186	of	_	_	
22-129	4187-4190	the	_	_	
22-130	4191-4198	nuclear	_	_	
22-131	4199-4208	transport	_	_	
22-132	4209-4214	agent	_	_	
22-133	4215-4217	to	_	_	
22-134	4218-4221	the	_	_	
22-135	4222-4225	DNA	_	_	
22-136	4226-4234	molecule	_	_	
22-137	4234-4235	.	_	_	
22-138	4235-4236	"	_	_	
